Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

STRUGGLING to keep up with her two young children and dreading her own reflection in the mirror, Emma Lasenby knew something ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Josh Gad opened up about losing 40 pounds since he began taking GLP-1 medication, the class of drug that includes Ozempic ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

An ideal Mounjaro diet plan should focus on nutrient ... Meaning, it mimics both the GIP and GLP-1 hormones in the body and, in doing so, increases the amount of insulin released after eating ...